Genes help explain GLP‑1 results

Glucagon-like peptide 1 drugs work by copying a gut hormone your body already uses after a meal. That hormone tells the brain you’ve eaten, slows how fast food leaves the stomach, and pushes the pancreas to release insulin when blood sugar rises. (scientificamerican.com) That slowdown is part of why these medicines cut appetite, and it is also part of why nausea is so common. The same signal that helps one person feel full can make another person feel sick after the first few doses. (scientificamerican.com) The puzzle is that people on the same drug can have very different results. Some lose less than 5% of their body weight, while others lose more than 20%, and side effects vary just as widely. (nature.com) A study published in Nature on April 8 looked for one reason why by comparing DNA from nearly 28,000 people who reported taking these drugs. The researchers used data from 23andMe participants who had also reported their weight change and whether they had nausea or vomiting. (nature.com) They found one important signal in a gene called GLP1R, which is the instruction code for the receptor these drugs latch onto. You can picture that receptor as a lock and the drug as a key: a small inherited change in the lock can change how strongly the key works. (nature.com) People carrying a specific GLP1R variant lost about 0.76 kilograms more per copy of that variant than non-carriers. The same gene was also linked to nausea and vomiting risk, which means the drug target itself seems to shape both benefit and side effects. (nature.com) The team also found a second signal in GIPR, a gene tied to another gut-hormone receptor. That variant was linked to nausea and vomiting mainly in people taking tirzepatide, which hits both the glucagon-like peptide 1 pathway and the glucose-dependent insulinotropic polypeptide pathway. (nature.com) That drug-specific result fits the biology. Semaglutide mainly targets the glucagon-like peptide 1 receptor, while tirzepatide targets both receptors, so a variant in GIPR would be expected to matter more for tirzepatide users. (nature.com) The genes did not explain everything. Scientific American reported that the variants account for only part of the gap between people who respond dramatically and people who barely respond, which means dose, adherence, diet, other medicines, and health conditions still matter too. (scientificamerican.com) But the study did something medicine rarely gets to do this cleanly: it tied inherited DNA differences directly to the drug’s target and then to real-world outcomes. The authors say those signals could eventually help sort patients by expected weight loss and by side-effect risk before treatment starts. (nature.com)